{"Clinical Trial ID": "NCT02139358", "Intervention": ["INTERVENTION 1:", "Dose Escalation / Phase II Treatment", "One single arm, non-randomized, open phase I/II multisite Simon tries two minimal steps. Gemcitabine plus trastuzumab and pertuzumab."], "Eligibility": ["Incorporation criteria:", "Adult men or women (aged 18 years or older) with metastatic human epidermal growth factor receptor 2 (HER2)+ (by immunohistochemistry (IHC) 3+ or in situ fluorescence (FISH) 2.0) breast cancer", "\u2022 T-DM1 would be considered a treatment line and patients previously treated with T-DM1 are eligible.", "Not treated with gemcitabine in the metastatic context", "A Measurable Disease by Response Assessment in Solid Tumours (RECIST) 1.1 Criteria", "Statement of Operations of the Eastern Cooperative Oncology Group (ECOG) 2", "- Left ventricular ejection (LVEF) 50% inclusion as determined by echocardiogram (ECHO) or multi-door acquisition analysis (MUGA)", "adequate bone marrow function as indicated by: absolute neutrophil count (NAC) >150/\u03bcL; platelets 100 000/\u03bcL; hemoglobin >10 g/dL", "Adequate renal function as indicated by 1.5x upper limit of normal creatinine (ULN)", "adequate liver function as indicated by bilirubin 1.5x ULN, aspartic transaminase (AST) or alanine transaminase (ALT) <2x ULN, unless linked to metastatic breast cancer in the liver (in this case, AST/ALT < 5x ULN is allowed).", "Signed informed consent", "Adequate birth control among sexually active women of childbearing age", "- Exclusion criteria:", "\u2022 An uncontrolled active infection or a major concomitant disease which, in the opinion of the investigator, would make the participant dangerous to continue the study", "Uncontrolled central nervous system (CNS) metastases. CNS disease (documented by brain magnetic resonance imaging [MRI]) treated and not in progression of corticosteroids for at least one month is eligible.", "Pregnant or lactating women", "Previous chemotherapy in the last 3 weeks (last 6 weeks for nitrosurees/mitomycin)", "Previous radiation therapy in the last 4 weeks; prior radiation therapy to indicate injury (unless the recurrence or objective progression of the disease within the radiation portal has been documented since the radiation was completed)", "Other concomitant active malignancies", "\u2022 History of major heart disease, cardiac risk factors or uncontrolled arrhythmias", "- Ejection fraction less than or equal to 50% of the lower limit of the institutional normal range, whichever is lower.", "\u2022 Hypersensitivity to one of the study drugs", "Untreated psychiatric disorders preventing informed consent"], "Results": ["Performance measures:", "Phase I: Recommended dose for Phase II (RP2D)", "The dose of RP2D in mg/m^2 gemcitabine and the standard doses of pertuzumab (840 mg maintenance charge/420 mg) and Herceptin (8 mg/kg maintenance charge, 6 mg/kg maintenance).", "Time limit: 6 months", "Results 1:", "Title of the arm/group: Dose escalation / Phase II treatment", "Description of the arm/group: Single arm, non-randomized, open phase I/II multisite Simon try two minimal steps. Gemcitabine plus trastuzumab and pertuzumab.", "Total number of participants analysed: 6", "Type of measurement: Number", "Unit of measurement: dose in mg/m2 1200"], "Adverse Events": ["Undesirable Events 1:", "Total: 7/15 (46.67 per cent)", "Cardiac arrest * 1/15 (6.67%)", "Cardiac chest pain * 1/15 (6.67%)", "Diarrhoea * 1/15 (6.67 per cent)", "* 1/15 (6.67 per cent)", "Fatigue * 1/15 (6.67 per cent)", "Fever * 1/15 (6.67 per cent)", "- Sudden death NOS * 1/15 (6.67 per cent)", "Sepsis * 1/15 (6.67 per cent)", "Skin infection * 1/15 (6.67%)", "Decrease in neutrophil count * 1/15 (6.67 per cent)", "Decrease in platelet count * 1/15 (6.67 per cent)"]}